seralutinib
seralutinib: sourced relationships with 1 company · 3 clinical trials tracked.
seralutinib evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could seralutinib → GOSS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| Gossamer Bio, Inc. (GOSS) | Phase 3 |
| Gossamer Bio, Inc. (GOSS) | Phase 3 |
Clinical Trial Registry Records (3)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) Followed by a Long-Term Extension Evaluating Safety and Efficacy
Primary endpoint: Change in distance achieved on the six-minute walk test (6MWT), from baseline to PCP Week 24
An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arterial Hypertension (PAH)
Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)
Primary endpoint: Change in distance achieved on the six-minute walk test (6MWT), six-minute walk distance (Δ6MWD) from baseline to Week 24
Frequently asked questions
Which companies have sourced relationships with seralutinib?
seralutinib has dated SEC/FDA relationship records for Gossamer Bio, Inc..
How many clinical trials involve seralutinib?
BioSniper tracks 3 clinical trials involving seralutinib.